- Poster presentation
- Open Access
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece
© Panagopoulos et al; licensee BioMed Central Ltd. 2010
- Published: 8 November 2010
- Total Bilirubin
- Type Locus
- Common Adverse Event
Over the past few years there has been a remarkable increase in our knowledge of the variation in human genome. In parallel genotyping technologies have advanced significantly and allow sufficient throughput to accommodate genome-wide approaches. Hyperbilirubinemia is the most common adverse event in patients treated with atazanavir (ATV). Previous studies showed that polymorphisms in the uridine-glucuronosyl transferase (UGT1A1) enzyme and specifically the UGT1A1*28 variant may influence the risk of hyperbilirubinemia in patients treated with ATV/r.
Our objective was to estimate the prevalence of UGT1A1*28 polymorphism in HIV-infected individuals in Greece and to determine its potential association with hyperbilirubinemia in patients receiving boosted ATV (ATV/r).
The prevalence of the UGTA1A1*28 variant was estimated in 80 HIV-infected patients retrospectively, (4/2009-5/2010) prior to the administration of the first-line treatment. Wilcoxon rank-sum test was used to determine whether the total bilirubin levels were different among carriers and non-carriers of the UGT1A1*28 polymorphism. The presence of the UGT1A1*28 allele was detected by PCR and DNA electrophoresis.
The UGTA1A1*28 variant was detected in 45 out of 80 individuals (56.25%). Among 55 patients who received HAART, 20 received ATV/r as part of their first treatment. Of the ATV/r treated patients, 13 were found to be carriers of the UGT1A1*28 variant (65%). Total bilirubin levels were significantly higher in patients harbouring the UGT1A1*28 polymorphism (median value: 5.15 mg/dl) versus those harbouring the wild type UGT1A1 locus (median value mg/dl: 1.30) (p<0.01). The higher value of bilirubin was observed at week 4 of treatment whereas only 3 patients switched ATV/r to other Protease Inhibitor due to aesthetic problems. Hyperbilirubinemia (total bilirubin >1.3 mg/dl) was not detected in any patient with the UGT11A1*28 variant receiving any other therapy than ATV/r based first-line regimens.
Notably, 56% of the HIV-infected patients from a single HIV Unit in Greece carry at least one copy of the UGT1A1*28 allele. Carriers of the UGT1A1*28 variant treated with ATV/r based regimens had significantly higher levels of total bilirubin than those with UGT1A1 wild type locus, thus, suggesting the clinical utility of the UGT1A1 testing prior the administration of first-line treatment.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.